Roth Capital Issues Optimistic Outlook for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at Roth Capital upped their Q1 2025 earnings estimates for shares of Zevra Therapeutics in a research note issued to investors on Tuesday, March 11th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings of ($0.17) per share for the quarter, up from their previous estimate of ($0.27). The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics' Q2 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at ($0.10) EPS, FY2026 earnings at $0.81 EPS, FY2027 earnings at $1.38 EPS and FY2028 earnings at $1.79 EPS.

Other research analysts have also issued reports about the stock. Guggenheim increased their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group increased their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Finally, JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $22.29.

Remove Ads

Zevra Therapeutics Trading Down 4.6 %

NASDAQ:ZVRA traded down $0.38 on Friday, reaching $7.97. The stock had a trading volume of 319,016 shares, compared to its average volume of 574,467. The company has a market cap of $431.30 million, a price-to-earnings ratio of -4.05 and a beta of 1.98. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The firm's fifty day moving average is $7.92 and its two-hundred day moving average is $8.17. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The firm had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%.

Insider Buying and Selling

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the transaction, the chief executive officer now directly owns 222,060 shares in the company, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the transaction, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. This trade represents a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 85,773 shares of company stock worth $674,176 over the last ninety days. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ZVRA. Adage Capital Partners GP L.L.C. grew its holdings in Zevra Therapeutics by 462.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock worth $30,441,000 after acquiring an additional 3,001,000 shares during the period. FMR LLC increased its stake in Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company's stock worth $16,054,000 after purchasing an additional 2,312,384 shares in the last quarter. AIGH Capital Management LLC purchased a new position in Zevra Therapeutics in the 4th quarter worth about $6,577,000. Stonepine Capital Management LLC purchased a new position in Zevra Therapeutics in the 3rd quarter worth about $4,858,000. Finally, Vestal Point Capital LP purchased a new position in Zevra Therapeutics in the 3rd quarter worth about $3,644,000. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.